HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction
about
Association between maternal HIV infection and low birth weight and prematurity: a meta-analysis of cohort studiesEfficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model.Multiple Overimputation to Address Missing Data and Measurement Error: Application to HIV Treatment During Pregnancy and Pregnancy OutcomesRisk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?Preterm Birth and Low Birth Weight after In Utero Exposure to Antiretrovirals Initiated during Pregnancy in Yaoundé, CameroonThe Use of Protease Inhibitors in Pregnancy: Maternal and Fetal Considerations.Paediatric HIV: Progress on Prevention, Treatment and CureReassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in BotswanaDuration of cART Before Delivery and Low Infant Birthweight Among HIV-Infected Women in Lusaka, Zambia.Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.Increasing Number and Proportion of Adverse Obstetrical Outcomes among Women Living with HIV in the Ottawa Area: A 20-Year Clinical Case Series.Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trialBenefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.Impact of maternal HIV-1 infection on the feto-maternal crosstalk and consequences for pregnancy outcome and infant health.Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.Perceived acceptability of progesterone to prevent preterm births and low birth weight among HIV-infected and HIV-uninfected Zambian pregnant women.Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV.Elevated Levels of Estradiol in Human Immunodeficiency Virus-Infected Pregnant Women on Protease Inhibitor-Based Regimens.Antiretroviral therapy use during pregnancy and adverse birth outcomes in South African women.Preconception use of cART by HIV-positive pregnant women increases the risk of infants being born small for gestational age.Adverse effects in children exposed to maternal HIV and antiretroviral therapy during pregnancy in Brazil: a cohort study.Surviving and Thriving-Shifting the Public Health Response to HIV-Exposed Uninfected Children: Report of the 3rd HIV-Exposed Uninfected Child Workshop.HIV antiretroviral exposure in pregnancy induces detrimental placenta vascular changes that are rescued by progesterone supplementation.
P2860
Q26785714-1D1195A8-2A1D-4194-BF15-7FDFCFA53E68Q30395163-EA741C2E-B602-4473-967D-9DF44DE41A61Q31070972-78696D4A-E4FE-4D36-9DE3-F10883FCC292Q35691443-DB619E0C-D04E-48C0-86CE-C8A4B1CB6000Q35964999-8E1B4CEF-34E1-40F6-87EA-10832A2CF326Q36296422-6AD0C176-3435-4D4A-AE34-32B11826EEBBQ36395153-4BB80813-3F30-420E-ABC9-7CE048A0C2A2Q36619600-02333611-3C3B-4AFF-AF9C-B88748C0FCB8Q36678190-29A14898-FCB7-4BC2-B7C3-451A4E267FC1Q36816616-86B55CAB-5640-4AD2-A966-FE9F5A2F225DQ37162809-755EE5E6-B56E-4337-B8FE-11159D91D58AQ37498149-9036877F-08DB-48F4-A219-7E4DAFED2639Q37558394-01D901E7-5EBF-4166-9E37-29157DA9F10CQ38636802-4720EA8C-659B-40E0-B68D-4BD9C6FD7699Q38890564-7DE0A032-1EFA-4887-BBCA-E10CBD0B0BB5Q45324863-FE6EB3ED-5B5E-4780-969B-949CA78003EBQ46502334-587675E3-17C0-404B-9321-C80916725DD3Q47162116-212595A2-CA6D-4AA0-838D-61A1526A2C68Q47616851-334C94E4-60D5-48DE-85E4-A4C1E172A844Q47776480-1593BB28-966C-4D60-89AB-8EC70E776304Q48206030-7C764F84-DD3F-4ECD-A3B5-8FC2CC41BAC1Q54215199-0E8FD052-559E-456F-BB05-F4DD2156E6B4Q55101336-C7449DEA-C114-49D6-A779-E36124816D38Q55394797-E4E43494-D3A5-4C33-B646-1504F7877677
P2860
HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
HIV protease inhibitor use dur ...... ng to fetal growth restriction
@ast
HIV protease inhibitor use dur ...... ng to fetal growth restriction
@en
HIV protease inhibitor use dur ...... ng to fetal growth restriction
@nl
type
label
HIV protease inhibitor use dur ...... ng to fetal growth restriction
@ast
HIV protease inhibitor use dur ...... ng to fetal growth restriction
@en
HIV protease inhibitor use dur ...... ng to fetal growth restriction
@nl
prefLabel
HIV protease inhibitor use dur ...... ng to fetal growth restriction
@ast
HIV protease inhibitor use dur ...... ng to fetal growth restriction
@en
HIV protease inhibitor use dur ...... ng to fetal growth restriction
@nl
P2093
P2860
P50
P356
P1476
HIV protease inhibitor use dur ...... ng to fetal growth restriction
@en
P2093
Eszter Papp
Hakimeh Mohammadi
Jay MacGillivray
Mark H Yudin
Michael Silverman
Mona R Loutfy
Rajiv Shah
P2860
P356
10.1093/INFDIS/JIU393
P407
P577
2014-07-16T00:00:00Z